2010•Int J Radiat Med Nuel MedRequires access

Progress of study on the molecular imaging and targeted therapy in CD20 of non Hodgkin' s lymphoma

Lin Zha, Shibin Feng, Qianwei Li

Abstract

The molecular imaging and targeted therapy with radiolabeled anti-CD20 monoclonal antibody or recombinant anti-CD20 monoclonal antibody fragments is the effective methods to improve the survival rate for non-Hodgkin' s lymphoma (NHL). This article reviews the biological characteristics of CD20 and the immunotherapy, radioimmunotherapy, radioimmunoimaging with anti-CD20 monoclonal antibody for NHL. Key words: Non-Hodgkin' s lymphoma; Cluster of differentiation 20; Rituximab; Immunotherapy; Radioimmunoimaging

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Radioimmunotherapy, Monoclonal antibody, Lymphoma, Rituximab, CD20, Non-Hodgkin's lymphoma, Immunotherapy, Monoclonal antibody therapy